Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.41 |
| ▸ | HTR3B | O95264 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 4/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2869584 | 0.94 | BPTF (0.50) | BPTFHSD17B10KDM4ECYP3A4HTR2C | |
| SCHEMBL29942240 | 0.85 | BPTF (0.54) | BPTFHSD17B10KDM4ECYP3A4ALDH1A1 | |
| SCHEMBL20021209 | 0.83 | CYP1A2 (0.53) | ALDH1A1HTTCYP1A2LMNA | |
| Hydrochloric Acid SCHEMBL25228190 | 0.80 | KMT2A (0.51) | BPTFHSD17B10KDM4ECYP3A4HTR3A | |
| SCHEMBL64557 | 0.80 | NPC1 (0.47) | KDM4EALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL22557496 | 0.80 | LMNA (0.41) | HTTLMNA | |
| SCHEMBL607319 | 0.80 | CNR2 (0.56) | HSD17B10KDM4EALDH1A1HTTLMNA | |
| SCHEMBL15754487 | 0.79 | LMNA (0.50) | HTTLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30263381 | 0.79 | CNR2 (0.55) | HSD17B10KDM4EALDH1A1HTTLMNA | |
| SCHEMBL9838734 | 0.78 | KDM4E (0.51) | BPTFHSD17B10KDM4ECYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-2316827-B1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NOVARTIS PHARMA AG (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2257291-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | Xenon Pharmaceuticals Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-7759348-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-07-20 | — | — | US | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| EP-1851205-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-07 | — | — | EP | disclosed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | BPTF 4636/4885HSD17B10 2770/4885KDM4E 1401/4885 |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | BPTF 4625/4885HSD17B10 2537/4885KDM4E 1192/4885 |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | SCD, SCD5, NR1H2 | BPTF 3332/4885HSD17B10 55/4885KDM4E 901/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | BPTF 1414/4885HSD17B10 1255/4885KDM4E 1910/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | BPTF 4649/4885HSD17B10 2659/4885KDM4E 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.